<DOC>
	<DOCNO>NCT00619619</DOCNO>
	<brief_summary>The primary purpose study test safety tolerability single ascending dos Desvenlafaxine Succinate Sustained-Release ( DVS SR ) child adolescent outpatient major depressive disorder . This study also characterize pharmacokinetic profile DVS SR child adolescent major depressive disorder .</brief_summary>
	<brief_title>Study Evaluating Desvenlafaxine Succinate Sustained-Release ( DVS SR ) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Male female outpatient 7 17 year age baseline meet Diagnostic Statistic Manual Mental Disorders , Fourth Edition , Text Revision criterion major depressive disorder . Children 's Depression Rating Scale Revised ( CDRSR ) score great 40 screen study day 1 ( baseline ) visit Clinical Global Impressions ScaleSeverity ( CGIS ) score great equal 4 screening study day 1 ( baseline ) visit . Depression least moderate severity symptom least 1 month screening could , investigator ` opinion , respond therapy antidepressant ( ) alone ( without concomitant psychotherapy ) . Other inclusion criterion apply . History current evidence medical condition know interfere absorption excretion drug history surgery know interfere absorption excretion drug ; history presence medical condition might confound study put study participant great risk participation ; know hypersensitivity venlafaxine . History suicide attempt gesture intent suicide serious selfharm acute suicidality degree precaution suicide must exercise . Current ( within 12 month baseline ) psychoactive substance abuse dependence ( include alcohol ) , manic episode , posttraumatic stress disorder , obsessivecompulsive disorder , diagnosis bipolar disorder psychotic disorder current ( within 12 month baseline ) generalize anxiety disorder , panic disorder , social anxiety disorder , attention deficit hyperactivity disorder ( ADHD ) consider investigator primary ( cause high degree distress impairment MDD ) presence ( within 12 month baseline ) clinically important personality disorder ( antisocial , schizotypal , histrionic , borderline , narcissistic ) assess psychiatric evaluation history presence MDD psychotic feature . Other exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>MDD</keyword>
	<keyword>Child</keyword>
	<keyword>Adolescent</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Outpatient</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Depressive Disorder</keyword>
	<keyword>Major</keyword>
</DOC>